Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor
Cancer Detection and Prevention, Volume 32, No. 4, Year 2009
Notification
URL copied to clipboard!
Description
Introduction: Enzyme-linked immunosorbent assay (ELISA) was used for analysis of serum mutant p53 protein, carcinoembryonic antigen (CEA), and epidermal growth factor receptor (EGFR). Serum samples were obtained from 48 patients with colorectal cancer (CRC) and a control group of twenty healthy individuals. Results: The results demonstrated a significant increase of serum mutant p53, EGFR, and CEA levels in CRC patients compared to the control group (P < 0.001 for each). Mutant p53 protein was significantly different in the different CRC grades (P = 0.028). p53, CEA, and EGFR can differentiate successfully between different CRC grades and normal control (P < 0.001 for each). Sensitivities of p53, CEA, and EGFR were 39.6, 31, and 71%, respectively. There was no correlation between CEA, EGFR, and p53 indicating that these variables were independent. Positive status of serum CEA and (or) p53 was found in 29 out of 48 (60%) patients. Also, positive status of serum CEA and (or) EGFR was found in 39 out of 48 (81%) patients. Conclusion: Thus, the simultaneous determination of p53 or EGFR combined with the CEA may increase the sensitivity to diagnose CRC patients and may aid in disease prognosis. © 2006 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Abdel-Aziz, Mohamed Mohamed
Egypt, Mansoura
Gastrointestinal Surgery Center
Lotfy, Mahmoud
Egypt, Shibin el Kom
Menoufia University
El-Kady, Ibrahim M.
Egypt, Shibin el Kom
Menoufia University
Abozaid, Mostafa
Egypt, Mansoura
Faculty of Medicine
Statistics
Citations: 16
Authors: 4
Affiliations: 3
Identifiers
Doi:
10.1016/j.cdp.2005.10.006
ISSN:
0361090X
Research Areas
Cancer
Study Design
Randomised Control Trial